

# oholic Steatohepatitis (NASH)-Global Market Status and Trend Report 2013-2023

https://marketpublishers.com/r/OF1959E9A84EN.html

Date: December 2017

Pages: 143

Price: US\$ 2,480.00 (Single User License)

ID: OF1959E9A84EN

### **Abstracts**

### **Report Summary**

oholic Steatohepatitis (NASH)-Global Market Status and Trend Report 2013-2023 offers a comprehensive analysis on oholic Steatohepatitis (NASH) industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:

Worldwide and Regional Market Size of oholic Steatohepatitis (NASH) 2013-2017, and development forecast 2018-2023

Main manufacturers/suppliers of oholic Steatohepatitis (NASH) worldwide, with company and product introduction, position in the oholic Steatohepatitis (NASH) market Market status and development trend of oholic Steatohepatitis (NASH) by types and applications

Cost and profit status of oholic Steatohepatitis (NASH), and marketing status Market growth drivers and challenges

The report segments the global oholic Steatohepatitis (NASH) market as:

Global oholic Steatohepatitis (NASH) Market: Regional Segment Analysis (Regional Production Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

North America
Europe
China
Japan



### **Rest APAC**

Latin America

Global oholic Steatohepatitis (NASH) Market: Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

Weight Loss Treatment
Insulin-Sensitizing Agents
Lipid-Lowering Drugs
Antioxidants
Other Agents

Global oholic Steatohepatitis (NASH) Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

Hospital

Clinics

**Drug Store** 

Research institute

Others

Global oholic Steatohepatitis (NASH) Market: Manufacturers Segment Analysis (Company and Product introduction, oholic Steatohepatitis (NASH) Sales Volume, Revenue, Price and Gross Margin):

Boehringer Ingelheim

Cerenis Therapeutics

Connexios Life Sciences

Genfit

Islet Sciences

Nimbus Therapeutics

Verva Pharmaceuticals

Viking Therapeutics

Astazeneca Plc

Galmed Pharmaceuticals Ltd.

**GENFIT SA** 

Gilead Science

Novo Nordisk

Immuron Ltd



Intercepts Pharmaceuticals Enzo Biochem, Inc Tobira Therapeutics, Inc.

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.



### **Contents**

### **CHAPTER 1 OVERVIEW OF OHOLIC STEATOHEPATITIS (NASH)**

- 1.1 Definition of oholic Steatohepatitis (NASH) in This Report
- 1.2 Commercial Types of oholic Steatohepatitis (NASH)
  - 1.2.1 Weight Loss Treatment
  - 1.2.2 Insulin-Sensitizing Agents
  - 1.2.3 Lipid-Lowering Drugs
  - 1.2.4 Antioxidants
  - 1.2.5 Other Agents
- 1.3 Downstream Application of oholic Steatohepatitis (NASH)
  - 1.3.1 Hospital
  - 1.3.2 Clinics
- 1.3.3 Drug Store
- 1.3.4 Research institute
- 1.3.5 Others
- 1.4 Development History of oholic Steatohepatitis (NASH)
- 1.5 Market Status and Trend of oholic Steatohepatitis (NASH) 2013-2023
- 1.5.1 Global oholic Steatohepatitis (NASH) Market Status and Trend 2013-2023
- 1.5.2 Regional oholic Steatohepatitis (NASH) Market Status and Trend 2013-2023

### **CHAPTER 2 GLOBAL MARKET STATUS AND FORECAST BY REGIONS**

- 2.1 Market Development of oholic Steatohepatitis (NASH) 2013-2017
- 2.2 Production Market of oholic Steatohepatitis (NASH) by Regions
  - 2.2.1 Production Volume of oholic Steatohepatitis (NASH) by Regions
  - 2.2.2 Production Value of oholic Steatohepatitis (NASH) by Regions
- 2.3 Demand Market of oholic Steatohepatitis (NASH) by Regions
- 2.4 Production and Demand Status of oholic Steatohepatitis (NASH) by Regions
- 2.4.1 Production and Demand Status of oholic Steatohepatitis (NASH) by Regions 2013-2017
- 2.4.2 Import and Export Status of oholic Steatohepatitis (NASH) by Regions 2013-2017

#### **CHAPTER 3 GLOBAL MARKET STATUS AND FORECAST BY TYPES**

- 3.1 Production Volume of oholic Steatohepatitis (NASH) by Types
- 3.2 Production Value of oholic Steatohepatitis (NASH) by Types



3.3 Market Forecast of oholic Steatohepatitis (NASH) by Types

### CHAPTER 4 GLOBAL MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY

- 4.1 Demand Volume of oholic Steatohepatitis (NASH) by Downstream Industry
- 4.2 Market Forecast of oholic Steatohepatitis (NASH) by Downstream Industry

## CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF OHOLIC STEATOHEPATITIS (NASH)

- 5.1 Global Economy Situation and Trend Overview
- 5.2 oholic Steatohepatitis (NASH) Downstream Industry Situation and Trend Overview

### CHAPTER 6 OHOLIC STEATOHEPATITIS (NASH) MARKET COMPETITION STATUS BY MAJOR MANUFACTURERS

- 6.1 Production Volume of oholic Steatohepatitis (NASH) by Major Manufacturers
- 6.2 Production Value of oholic Steatohepatitis (NASH) by Major Manufacturers
- 6.3 Basic Information of oholic Steatohepatitis (NASH) by Major Manufacturers
- 6.3.1 Headquarters Location and Established Time of oholic Steatohepatitis (NASH) Major Manufacturer
- 6.3.2 Employees and Revenue Level of oholic Steatohepatitis (NASH) Major Manufacturer
- 6.4 Market Competition News and Trend
  - 6.4.1 Merger, Consolidation or Acquisition News
  - 6.4.2 Investment or Disinvestment News
  - 6.4.3 New Product Development and Launch

### CHAPTER 7 OHOLIC STEATOHEPATITIS (NASH) MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA

- 7.1 Boehringer Ingelheim
  - 7.1.1 Company profile
  - 7.1.2 Representative oholic Steatohepatitis (NASH) Product
- 7.1.3 oholic Steatohepatitis (NASH) Sales, Revenue, Price and Gross Margin of Boehringer Ingelheim
- 7.2 Cerenis Therapeutics
  - 7.2.1 Company profile



- 7.2.2 Representative oholic Steatohepatitis (NASH) Product
- 7.2.3 oholic Steatohepatitis (NASH) Sales, Revenue, Price and Gross Margin of Cerenis Therapeutics
- 7.3 Connexios Life Sciences
  - 7.3.1 Company profile
  - 7.3.2 Representative oholic Steatohepatitis (NASH) Product
- 7.3.3 oholic Steatohepatitis (NASH) Sales, Revenue, Price and Gross Margin of Connexios Life Sciences
- 7.4 Genfit
  - 7.4.1 Company profile
- 7.4.2 Representative oholic Steatohepatitis (NASH) Product
- 7.4.3 oholic Steatohepatitis (NASH) Sales, Revenue, Price and Gross Margin of Genfit
- 7.5 Islet Sciences
  - 7.5.1 Company profile
  - 7.5.2 Representative oholic Steatohepatitis (NASH) Product
- 7.5.3 oholic Steatohepatitis (NASH) Sales, Revenue, Price and Gross Margin of Islet Sciences
- 7.6 Nimbus Therapeutics
  - 7.6.1 Company profile
  - 7.6.2 Representative oholic Steatohepatitis (NASH) Product
- 7.6.3 oholic Steatohepatitis (NASH) Sales, Revenue, Price and Gross Margin of Nimbus Therapeutics
- 7.7 Verva Pharmaceuticals
  - 7.7.1 Company profile
  - 7.7.2 Representative oholic Steatohepatitis (NASH) Product
- 7.7.3 oholic Steatohepatitis (NASH) Sales, Revenue, Price and Gross Margin of Verva Pharmaceuticals
- 7.8 Viking Therapeutics
  - 7.8.1 Company profile
  - 7.8.2 Representative oholic Steatohepatitis (NASH) Product
- 7.8.3 oholic Steatohepatitis (NASH) Sales, Revenue, Price and Gross Margin of Viking Therapeutics
- 7.9 Astazeneca Plc
  - 7.9.1 Company profile
  - 7.9.2 Representative oholic Steatohepatitis (NASH) Product
  - 7.9.3 oholic Steatohepatitis (NASH) Sales, Revenue, Price and Gross Margin of

### Astazeneca Plc

- 7.10 Galmed Pharmaceuticals Ltd.
- 7.10.1 Company profile



- 7.10.2 Representative oholic Steatohepatitis (NASH) Product
- 7.10.3 oholic Steatohepatitis (NASH) Sales, Revenue, Price and Gross Margin of Galmed Pharmaceuticals Ltd.
- 7.11 GENFIT SA
- 7.11.1 Company profile
- 7.11.2 Representative oholic Steatohepatitis (NASH) Product
- 7.11.3 oholic Steatohepatitis (NASH) Sales, Revenue, Price and Gross Margin of GENFIT SA
- 7.12 Gilead Science
  - 7.12.1 Company profile
  - 7.12.2 Representative oholic Steatohepatitis (NASH) Product
- 7.12.3 oholic Steatohepatitis (NASH) Sales, Revenue, Price and Gross Margin of Gilead Science
- 7.13 Novo Nordisk
  - 7.13.1 Company profile
  - 7.13.2 Representative oholic Steatohepatitis (NASH) Product
- 7.13.3 oholic Steatohepatitis (NASH) Sales, Revenue, Price and Gross Margin of Novo Nordisk
- 7.14 Immuron Ltd
  - 7.14.1 Company profile
  - 7.14.2 Representative oholic Steatohepatitis (NASH) Product
- 7.14.3 oholic Steatohepatitis (NASH) Sales, Revenue, Price and Gross Margin of Immuron Ltd
- 7.15 Intercepts Pharmaceuticals
  - 7.15.1 Company profile
  - 7.15.2 Representative oholic Steatohepatitis (NASH) Product
- 7.15.3 oholic Steatohepatitis (NASH) Sales, Revenue, Price and Gross Margin of Intercepts Pharmaceuticals
- 7.16 Enzo Biochem, Inc
- 7.17 Tobira Therapeutics, Inc.

## CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF OHOLIC STEATOHEPATITIS (NASH)

- 8.1 Industry Chain of oholic Steatohepatitis (NASH)
- 8.2 Upstream Market and Representative Companies Analysis
- 8.3 Downstream Market and Representative Companies Analysis

#### CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF OHOLIC



### **STEATOHEPATITIS (NASH)**

- 9.1 Cost Structure Analysis of oholic Steatohepatitis (NASH)
- 9.2 Raw Materials Cost Analysis of oholic Steatohepatitis (NASH)
- 9.3 Labor Cost Analysis of oholic Steatohepatitis (NASH)
- 9.4 Manufacturing Expenses Analysis of oholic Steatohepatitis (NASH)

### CHAPTER 10 MARKETING STATUS ANALYSIS OF OHOLIC STEATOHEPATITIS (NASH)

- 10.1 Marketing Channel
  - 10.1.1 Direct Marketing
  - 10.1.2 Indirect Marketing
- 10.1.3 Marketing Channel Development Trend
- 10.2 Market Positioning
  - 10.2.1 Pricing Strategy
  - 10.2.2 Brand Strategy
  - 10.2.3 Target Client
- 10.3 Distributors/Traders List

#### **CHAPTER 11 REPORT CONCLUSION**

#### CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE

- 12.1 Methodology/Research Approach
  - 12.1.1 Research Programs/Design
  - 12.1.2 Market Size Estimation
  - 12.1.3 Market Breakdown and Data Triangulation
- 12.2 Data Source
  - 12.2.1 Secondary Sources
  - 12.2.2 Primary Sources
- 12.3 Reference



#### I would like to order

Product name: oholic Steatohepatitis (NASH)-Global Market Status and Trend Report 2013-2023

Product link: https://marketpublishers.com/r/OF1959E9A84EN.html

Price: US\$ 2,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

### **Payment**

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <a href="https://marketpublishers.com/r/OF1959E9A84EN.html">https://marketpublishers.com/r/OF1959E9A84EN.html</a>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:	
Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <a href="https://marketpublishers.com/docs/terms.html">https://marketpublishers.com/docs/terms.html</a>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970